「LabTurbo」 was originally an automated nucleic acid department established by “Taigen Bioscience Co., Ltd." in 2000. For the past 20 years, it has focused on the development of nucleic acid application automation technology, product manufacturing and sales. It has successively developed more than 10 invention patents across Taiwan, the United States, China, Japan, South Korea, Germany and other countries, and began to deploy the global nucleic acid application market.
Based on the vigorous development of the global genetic testing market, 「 LabTurbo Biotech Co., Ltd.」was formally established in June 2019, and invested funds in the development of nucleic acid fully automated, full-process genetic testing systems, and strengthened the "AIO SP-qPCR" System Application Deepening" and "Global Market Layout".
LabTurbo products use the exclusive patented「flow membrane tube vacuum method」automatic nucleic acid extraction system, which has been adopted by the American Red Cross with ultra-high sensitivity. For four years, nearly 90,000 bags of blood transfusion of Lyme disease infected DNA Screening; the research results were published in the authoritative medical journal「The New England Journal of Medicine (NEJM)」and obtained the U.S. FDA medical materials certification. This result confirms that the company's branch automation products have reached international standards.
LabTurbos domestic customers cover nearly 40 institutions including hospitals at all levels, private inspection centers, universities, the Central Research Institute, the Food and Drug Administration of the Ministry of Health and Welfare, the Forensic Office of the Police Department, the Department of Disease Control, and the Animal Health Laboratory; The foreign customers are mainly the United States, and there are also product users in Israel, Singapore, and France. It is expected to continue to cultivate the global automated nucleic acid application market and expand the scope of automated genetic testing applications.